Schering to Float Genomics Business in 2001 -Reuters

Sep 06, 2000

NEW YORK, Sept 6 - German pharmaceuticals group Schering AG intends to float its functional genomics biotech business next year, Reuters reported on Wednesday.

Schering said that the offering would take place after the company raises as much as $35 million in venture capital for the unit.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

All So Similar

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A Very Long Time Ago Indeed

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

This Week in PNAS

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Genetic Condition to Drug Inspiration

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Main menu